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Summary
2-Hexadecynoic acid and 2-octadecynoic acid have
cidal activity against Mycobacterium smegmatis and
Mycobacterium bovis BCG. At subinhibitory concen-
trations, M. smegmatis rapidly transformed [1-14C]-2-
hexadecynoic acid into endogenous fatty acids and
elongated them into mycolic acids. Toxic concentra-
tions of 2-hexadecynoic acid resulted in accumulation
of 3-ketohexadecanoic acid, which blocked fatty acid
biosynthesis, and 3-hexadecynoic acid, an inhibitor
of fatty acid degradation. The combination of these
two metabolites is necessary to achieve the inhibition
ofM. smegmatis. We conclude that 2- and 3-hexa/octa-
decynoic acids inhibit mycolic acid biosynthesis, fatty
acid biosynthesis, and fatty acid degradation, path-
ways of significant importance for mycobacteria.
Introduction
Drug-resistant tuberculosis (TB) is a worldwide problem
in both human immunodeficiency virus-infected and im-
munocompetent populations [1]. Multidrug-resistant
Mycobacterium tuberculosis strains are resistant to sev-
eral first-line antituberculosis drugs, particularly isonia-
zid (INH) and rifampin [2]. Such strains are more difficult
and expensive to treat than drug-susceptible TB, and
they are more likely to be fatal, especially when diagno-
sis and appropriate therapy are delayed [3, 4]. It is clear
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Rosario, Argentina.that new, effective antituberculosis drugs are urgently
needed. Since its introduction in 1952, INH has been
the most effective antituberculosis drug for both the
treatment and prophylaxis of tuberculosis [5, 6]. Early
studies indicated that INH kills mycobacteria by inhibit-
ing mycolic acid biosynthesis [7]. Genetic studies deter-
mined that the target for INH is InhA [8], an enoyl-ACP re-
ductase that catalyzes the NADH-specific reduction of
2-trans-enoyl-ACP [9]. InhA inhibition by INH or loss of
function in an inhA temperature-sensitive mutant leads
to mycobacterial cell death [10]. Altogether, these re-
sults make InhA an attractive target for further drug de-
sign. Based on a structural model of InhA with an acyl
substrate [11], and the knowledge that this enzyme pref-
erentially reduces long-chain substrates (16–24 car-
bons) [9], we reasoned that substrate analogs, such as
long-chain 2-alkynoic acids, might competitively inhibit
InhA activity and consequently lead to mycobacterial
cell death. In this report, we present a study of the me-
tabolism and toxic effect of 2-alkynoic acids inM. smeg-
matis.
Results
The Activity of 2-Alkynoic Acids Depends on Chain
Length and Triple Bond Position
Previous work has shown that the enoyl-ACP reductase
of the type II fatty acid synthase (FASII) system, an en-
zyme encoded by the inhA gene [9, 12], involved in my-
colic acid biosynthesis and INH resistance in mycobac-
teria, is essential [10, 13]. In an effort to develop new
antimycobacterial drugs, we synthesized 2-alkynoic
acids, substrate analogs of InhA, which could presum-
ably act as competitive inhibitors of the enzyme. As an
initial screen for antimicrobial activity, 2-alkynoic acids
of varying chain lengths (from 12 to 24 carbon atoms)
were tested against the fast-growing, nonpathogenic
Mycobacterium smegmatis andCorynebacterium gluta-
micum, a related actinomycete. M. smegmatis was in-
hibited by 2-hexadecynoic acid (2-HA), 2-octadecynoic
acid (2-OA), and 2-nonadecynoic acid, with minimum in-
hibitory concentration (MIC) values of 2.5 mg/ml, 1 mg/ml,
and 10 mg/ml (10, 4, and 35 mM), respectively. Notably,
2-HA and 2-OA activities against M. smegmatis are
4- and 10-fold higher than the activity of INH, a first-
line antituberculosis drug (Table 1). The most active
compounds, 2-HA and 2-OA, were also active against
the slow grower M. bovis BCG, with MIC values of
4 mM and 9 mM, respectively (Table 1). Surprisingly,
2-HA was more active than 2-OA against M. bovis
BCG. This trend was also observed against the slow-
growing pathogenic M. tuberculosis H37Rv, with MICs
for 2-HA and 2-OA of 20 mM and 25 mM, respectively.
C. glutamicum was sensitive to 2-tetradecynoic acid
and 2-HA, with MIC values of 66 mM and 30 mM, respec-
tively (Table 1).
The effect of structural analogs of 2-HA/OA, the most
potent compounds against M. smegmatis, was also
studied by measuring the MIC values of isomers of HA
and OA with a triple bond at positions 2, 3, 4, or 5. The
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298Table 1. Minimum Inhibitory Concentration, mM, for Alkynoic Acids, Alkenoic Acids, and Isoniazid against M. smegmatis, C. glutamicum,








2-Dodecynoic acid CO2H >300 nd >300
2-Tetradecynoic acid CO2H 268 nd 66
2-Hexadecynoic acid CO2H 10 4 30
3-Hexadecynoic acid CO2H 20 nd nd
4-Hexadecynoic acid CO2H 30 nd nd
5-Hexadecynoic acid CO2H 80 nd nd
2-Octadecynoic acid CO2H 4 9 107
3-Octadecynoic acid CO2H 36 nd nd
4-Octadecynoic acid CO2H >360 nd nd
5-Octadecynoic acid CO2H 360 nd nd
2-Nonadecynoic acid CO2H 35 nd 204
2-Eicosynoic acid CO2H >300 nd nd






2-trans-Octadecenoic acid CO2H >200 nd >200
9-cis-Octadecenoic acid CO2H >200 nd >200
nd = not determined.inhibitory action was found to decrease when the triple
bond was located at a more distal position. Whereas
3-OA showed MIC values 10-fold higher than those for
2-OA, both 4-OA and 5-OA were almost inactive against
M. smegmatis (Table 1). In contrast, 3- and 4-HA dis-
played MIC values only 2- to 3-fold higher than that of
2-HA, whereas 5-HA needed an 8-fold increase in its
concentration to cause growth inhibition. Furthermore,
2-trans-octadecenoic acid, a long-chain fatty acid with
18 carbons like 2-OA, but a double bond instead of a tri-
ple bond at position 2, had no antimycobacterial activity
against M. smegmatis, indicating that the triple bond is
essential for the activity of these compounds (Table 1).
Thus, comparison of the structure-function activity dis-
played by alkynoic acid analogs clearly shows that the
inhibitory activity of this class of compounds depends
on both the chain length and the presence and position
of the triple bond.
The Activity of 2-Alkynoic Acids Is Not Due
to Nonspecific Fatty Acid-Mediated Lysis
The effect of 2-alkynoic acids on mycobacteria was
studied by growing cultures of M. bovis BCG or
M. smegmatis in the presence of increasing amounts
of 2-alkynoic acids. In M. bovis BCG, treatment with
2.5 mg/ml 2-HA or 2-OA resulted in a 3-log drop in col-ony-forming units (CFU)/ml after 3 days and a 4-log
drop in CFU/ml after 7 days (Figure 1A). In contrast,
in M. smegmatis, growth and cell viability were not
affected by low concentrations of 2-HA/OA (10 or
25 mg/ml), but high concentrations of 2-HA and 2-OA
(50 mg/ml) resulted in a 3- and 6-log decrease in the via-
ble counts over the course of one generation (Figure 1B)
followed by cell lysis. Interestingly, 3-HA required a lon-
ger time to affect cell viability even at 50 mg/ml, causing
a 4-log drop in CFUs after 7 hr, while 3-OA (at 50 mg/ml)
failed to significantly affect viability (Figure 1B). The re-
sults are consistent with the MIC data (Table 1), suggest-
ing that the potency of these compounds is in the order
2-OA > 2-HA > 3-HA > 3-OA. Treatment ofM. smegmatis
with palmitic acid (at 50 mg/ml) had no effect on growth
and cell viability. Since the concentration of 2-HA re-
quired for growth inhibition was 10- to 20-fold higher
than the MIC determined in solid medium, we studied
the role of the inoculum size on the inhibitory effect of
2-HA/OA in liquid medium. Low concentrations of 2-
HA/OA (1–2 mg/ml) inhibited growth of the mycobacterial
cultures started from small inoculum (105 CFU/ml), cor-
responding to the inoculum size used to determine the
MIC on solid media. In contrast, cultures started from
a larger inoculum size (107 CFU/ml) required a higher
concentration of compounds (up to 50 mg/ml) to display
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299Figure 1. Effect of Hexadecynoic and Octadecynoic Acids on the Growth of M. smegmatis
(A and B) Early-log phase cultures of (A)M.bovisBCG and (B)M. smegmatismc2155 were treated with DMSO solutions of 2-HA/OA (0.5–50 mg/ml)
and 3-HA/OA (50 mg/ml) for M. smegmatis. The addition of DMSO did not affect culture viability. Aliquots were taken, diluted, and plated.
CFUs were counted after 4 days of incubation for M. smegmatis or 3 weeks of incubation for M. bovis BCG at 37ºC. For clarity, the data ob-
tained for M. smegmatis treated with 2-HA (10 mg/ml and 25 mg/ml) and 2-OA (10 mg/ml) are not shown since they overlap with 2-OA (25 mg/ml).
The data in (B) are representative of three independent experiments.a comparable biological activity. Taken together, these
results suggest that alkynoic acids do not merely disrupt
the cell membrane by physical interaction, but act on
M. smegmatis through a specific mechanism.
Activity of 2-Alkynoic Acids against
the Enoyl-ACP Reductase InhA
Preliminary experiments examined the ability of long-
chain 2-alkynoic acids to act as competitive inhibitors
of InhA in vitro. The results obtained indicated that
2-HA and 2-OA, as their corresponding Coenzyme A
thioesters, acted as linear competitive inhibitors versus
2-trans-dodecenoyl-CoA with Kis = 2.16 0.6 mM (A. Que´-
mard, personal communication), resulting in inhibition of
mycolic acid biosynthesis [12].
Drugs that specifically inhibit InhA, such as INH, ethi-
onamide, triclosan, or diazaborine, induce the formation
of a 80 kDa protein consisting of a covalent complex
containing the b-ketoacyl-ACP synthase KasA and the
mycobacterial acyl carrier protein AcpM [14]. Immuno-
blot analysis with anti-KasA antibodies of M. smegmatis
cells treated with INH (5 mg/ml) revealed the induction of
this complex, in agreement with our previous observa-
tions (Figure 2). In order to assess whether inhA may
also be an in vivo target for 2-HA and 2-OA, M. smegma-
tis cells were treated with increasing concentrations of
2-HA or 2-OA (1–50 mg/ml) for 30 min and were analyzed
for the induction of the 80 kDa complex (Figure 2). Even
the lowest concentration of 2-HA or 2-OA tested re-
sulted in the formation of this complex, indicating that
both compounds inhibit InhA. Similar results were ob-
tained when cultures were treated for a longer period
of time (6 hr) with both compounds (data not shown).
Next, we determined the MIC values of 2-HA and 2-OA
on M. smegmatis mc22399, a strain bearing a multicopy
plasmid in which the inhA gene was placed under the
control of the hsp60 promoter [15]. Since overexpres-
sion of a primary drug target leads to resistance via titra-
tion of the drug, we hypothesized that overproduction of
InhA in this strain would confer enhanced resistance to
2-HA and 2-OA. Surprisingly, a low-level resistance to
2-HA and 2-OA was observed in mc22399. The MICs
against mc22399 for 2-HA and 2-OA were 32 mM and7 mM, respectively (a 3-fold and 2-fold increase, with
respect to wild-type M. smegmatis), while resistance
to INH, a specific inhibitor of InhA, increased up to
20-fold [15]. Thus, these results indicate that InhA is
not the primary target in vivo of 2-alkynoic acids and
suggest the existence of additional target(s).
Fatty Acid and Mycolic Acid Biosynthesis
in Mycobacteria Is Inhibited by 2-Alkynoic Acids
Mycobacteria have a complex system for the synthesis
of fatty acids, with prokaryotic (FASII)- and eukaryotic
(FASI)-like fatty acid synthetases [16]. FASI carries on
the synthesis of fatty acids (mainly C16:0 and C24:0),
while FASII elongates C16:0 to long-chain fatty acids,
which are the precursors of mycolic acids [16, 17]. To
understand at which level the inhibition by 2-alkynoic
acids takes place, the effect of increasing concentra-
tions of 2-HA and 2-OA on the de novo synthesis of fatty
Figure 2. 2-HA and 2-OA Induce a KasA-Containing Complex
Mid-log phase cultures of M. smegmatis were treated with increas-
ing concentrations of 2-HA (2.5–50 mg/ml) and 2-OA (1–50 mg/ml) for
30 min. INH (5 mg/ml) was used as a control for InhA inhibition.
Crude lysates were loaded on a 12% acrylamide gel and trans-
ferred to a membrane for immunoblot analysis. For the detection
of unbound KasA and the KasA-containing complex, the mem-
branes were probed with rat anti-KasA antibodies and then incu-
bated with anti-rat antibodies conjugated to alkaline phosphatase
prior to detection.
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300Figure 3. Dose-Response Effects of 2-HA,
3-HA, 2-OA, and 3-KHA on Fatty Acid and
Mycolic Acid Biosynthesis
(A) The effect of 2-HA on the incorporation of
[1-14C]-acetate was assayed by labeling
M. smegmatis in the presence of increasing
concentrations of 2-HA (10 mg/ml [lanes 1,
4, 7, and 10]; 25 mg/ml [lanes 2, 5, 8, and
11], or 50 mg/ml [lanes 3, 6, 9, and 12]) or in
the absence of drug (lane 13). 10% of total
counts were loaded in each lane.
(B) Mid-log phase cultures of M. bovis BCG
were treated with 2-HA or 2-OA (0, 2.5, 5,
and 10 mg/ml) and labeled with [1-14C]-ace-
tate.
(C) Mid-log phase M. smegmatis cultures
were treated with low concentrations of
2-HA or 2-OA and labeled with [1-14C]-ace-
tate.
(D) Log-phase cultures of M. smegmatis
were treated with 3-KHA (50 mg/ml, lanes 1,
6, and 11), 3-HA (10 mg/ml, lanes 2, 7, and
12; or 25 mg/ml, lanes 3, 8, and 13), or a com-
bination of 3-KHA (40 mg/ml) and 3-HA
(10 mg/ml [lanes 4, 9, and 14] or 25 mg/ml
[lanes 5, 10, and 15]) and labeled with
[1-14C]-acetate. Fatty acid methyl esters
(FAMEs) and mycolic acid methyl esters
(MAMEs) were extracted, analyzed, and de-
tected by autoradiography as described in
Experimental Procedures.acids was studied. Mid-log phase cultures of M. smeg-
matiswere grown in the presence of increasing amounts
of 2-alkynoic acids and were labeled with [1-14C]-ace-
tate. Fatty acids and mycolic acids were extracted and
analyzed by TLC and HPLC. De novo biosynthesis of
mycolic acids in cultures treated with either 2-HA or
2-OA (10, 25, or 50 mg/ml) was inhibited as early as
30 min after the addition of the compounds (Figure 3A).
In parallel, the synthesis of long-chain, nonhydroxylated
fatty acids was also severely diminished (Figure 3A). In-
creasing the concentration of 2-HA to 25 mg/ml inter-
fered with the de novo synthesis of fatty acids carried
on by the FASI system, causing a decrease of 80% in
the total incorporation of acetate into fatty acids. At
50 mg/ml, the inhibition of fatty acid synthesis was com-
plete (Figures 3A and 4A). The inhibition of the synthesis
of both fatty acids and mycolic acids continued un-
altered for up to 3 hr posttreatment for the higher con-
centrations of 2-alkynoic acids. However, at 10 mg/ml,
a partial restoration of mycolic acid biosynthesis was
observed after 90 min of treatment (Figure 3A). This tran-
sient inhibition observed at 10 mg/ml is in agreement
with the small effect that this concentration has on the
growth of the culture. Treatment ofM.bovisBCG with in-
creasing concentrations of 2-HA or 2-OA for 12 hr, fol-
lowed by [1-14C]-acetate labeling for 1 hr, showed thatmycolic acid biosynthesis is first inhibited at 5 mg/ml
for 2-HA and at 2.5 mg/ml for 2-OA. Fatty acid biosynthe-
sis is totally abrogated in the presence of 10 mg/ml of ei-
ther 2-HA or 2-OA (Figure 3B).
The synthesis of mycolic acids and fatty acids was
also analyzed in M. smegmatis cultures treated with
subinhibitory concentrations of drug. Under these con-
ditions, synthesis of mycolic acid was inhibited first
without affecting synthesis of fatty acids (Figure 3C),
which suggests that 2-alkynoic acids initially inhibit the
FASII system. In conclusion, our results show that
2-HA and 2-OA inhibit both FASI and FASII systems in
mycobacteria.
Alkynoic Acids Are Metabolized into Active Species
Previous studies on the effect of 2-HA on Streptococcus
mutans showed the presence of 2-HA in the bacterial
phospholipids [18]. Although 2-HA is less potent than
2-OA, the fact that [1-14C]-2-HA, but not [1-14C]-2-OA,
is commercially available prompted us to choose 2-HA
as a model by which to study the metabolism of 2-alky-
noic acids in mycobacteria. Addition of [1-14C]-2-HA to
M. smegmatis cultures yielded labeled mycolic acids,
phospholipids, and glycolipids (data not shown). To
confirm that these lipids incorporated unmodified
2-HA, the radiolabeled fatty acids extracted from
Activity of 2-Alkynoic Acids on Mycobacteria
301Figure 4. 2-HA Is Metabolized into Active Species that Inhibit Fatty Acid Biosynthesis
(A and B) M. smegmatis cultures treated with 0, 10, 25, or 50 mg/ml 2-HA were labeled with (A) [1-14C]-acetate or (B) [1-14C]-2-HA. [1-14C]-
Labeled fatty acids were extracted, derivatized to the corresponding p-bromophenacyl esters, and analyzed by HPLC. The identification
code and retention times for the principal p-bromophenacyl esters are as follows: (a) 10.9 min, C14:0; (b) 11.3 min, C16:1 cis-D9;
(c) 18.0 min, C16:0; (d) 19.5 min, C18:1 cis-D9; (e) 23.6 min, C18:0; (f) 24.1 min, 10-methyl-C18:0; (g) 25.2 min, C20:0; (h) 27.4 min, C 22:0;
(i) 29.8 min, C24:0; (j) 26.5 min, C22:1 trans-D2; (k) 28.8 min, C24:1 trans-D2; (l) 7.3 min, 3-hydroxyhexadecanoic acid; (m) 13.5 min, C16:1
trans-D3; (n) 7.5 min, 3-KHA; (o) 9.0 min, 3-HA; (x) 4.9 min, an unidentified compound.M. smegmatis cultures treated with [1-14C]-2-HA were
analyzed by HPLC. Surprisingly, instead of detecting
[1-14C]-2-HA, we observed a rapid (less than 30 min)
conversion of the label into endogenous fatty acids
(Figure 4B). In order to examine the pathway acting
upon 2-HA in mycobacteria, M. smegmatis cultures
were treated with increasing concentrations of 2-HA
for 30 min and labeled with [1-14C]-2-HA for another 30
min, and the extracted radiolabeled fatty acids were an-
alyzed by HPLC (Figure 4B). In the absence of 2-HA,
most of the label (68% of the total radioactivity) was
present as saturated fatty acids (C16:0–C24:0) and oleic
acid (11%). Two novel peaks identified as 3-hydroxy-
hexadecanoic acid (its stereochemistry was not deter-
mined) and 3-trans-hexadecenoic acid were also de-
tected, representing 10% and 11%, respectively, of
the total radioactivity. These two peaks were not present
in fatty acids extracted from M. smegmatis cultures la-
beled with [1-14C]-acetate (Figure 4A), indicating that
they were generated through metabolization of [1-14C]-
2-HA. A low concentration (10 mg/ml) of 2-HA did not af-
fect the distribution of the label. Increasing the concen-
tration to 25 mg/ml caused a decrease in the amount of
radiolabeled saturated (50%) and unsaturated (3-trans-
hexadecenoic acid [4%], oleic acid [< 0.1%]) fatty acids
and an increase in 3-hydroxyhexadecanoic acid (20%).
At the same time, two new compounds, 3-ketohexade-
canoic acid (3-KHA) (16%) and 3-HA (10%), were ob-
served. When the concentration of 2-HA was raised to
50 mg/ml, the labeled fatty acids consisted of 3-KHA
(70%), 3-HA (23%), and an unidentified, more polar com-
pound (7%), with no trace of saturated fatty acids, un-
saturated fatty acids, or 3-hydroxyhexadecanoic acid
(Figure 4B).Similar results were obtained when M. bovis BCG was
treated with 2-HA and labeled with [1-14C]-acetate or
[1-14C]-2-HA. [1-14C]-Acetate incorporation into fatty
acids was inhibited by the addition of 2-HA, as seen
for M. smegmatis (Figure 3B), while the metabolites de-
rived from labeled 2-HA were comparable to those de-
tected in M. smegmatis cultures.
As noted above, the activity of alkynoic acids de-
creased when the position of the triple bond was at
a more distal position. To test if this reduction in biolog-
ical activity correlates with a lack of metabolism of the
isomeric alkynoic acids, mid-log phase cultures of
M. smegmatis were treated with 2-, 3-, 4-, or 5-HA for
30 min, and the fatty acids were extracted and analyzed
by HPLC. 2-HA and 3-HA were not detected, but 4-HA
and 5-HA were found in the fatty acid extracts. The
same pattern was observed for 2-, 3-, 4-, and 5-OA, con-
firming that the shift in the position of the triple bond is
linked to the lack of activity. Incorporation of [1-14C]-
acetate by cultures of M. smegmatis treated with
3-HA, 2-OA, or 3-OA showed inhibition of M. smegmatis
FASI in a manner undistinguishable from that caused by
2-HA, indicating that these compounds also target FASI
and FASII. Taken together, these results suggest that al-
kynoic acids require a specific combination of chain
length and position of the triple bond and must be me-
tabolized in order to display biological activity.
Both Fatty Acid Degradation and Fatty Acid
Biosynthesis Systems Are Involved
in 2-HA Metabolism
2-Alkynoic acids incorporated by the mycobacterial cell
undergo reduction of the triple bond, yielding saturated
Chemistry & Biology
302Figure 5. Metabolism of 2-HA Occurs via a Functional FASI System
(A and B) [1-14C]-Fatty acids obtained from (A) labeling M. smegmatis cultures with [1-14C]-2-HA, [1-14C]-palmitic acid, [1-14C]-oleic acid,
[1-14C]-linoleic acid, or [1-14C]-linolenic acid or (B) after treatment of M. smegmatis cultures with cerulenin (5 mg/ml), 5-Cl-PZA (100 mg/ml),
or TLM (50 mg/ml), followed by labeling with [1-14C]-2-HA, were analyzed by HPLC.fatty acids (mainly palmitic acid) and oleic acid. The fact
that labeled fatty acids longer than the added precursor
(2-HA) are formed indicates that metabolites derived
from 2-HA are substrates for elongation by FASI and
FASII systems. The above-mentioned metabolites could
arise either by complete b-oxidation of the 2-HA, yield-
ing [1-14C]-acetate, which would be used in fatty acid
biosynthesis, or by a partial modification of 2-HA, yield-
ing primers for FASI. To discriminate between these
possibilities, two approaches were undertaken. First,
M. smegmatis cultures were labeled with [1-14C]-
palmitic acid, [1-14C]-oleic acid, [1-14C]-linoleic acid,
[1-14C]-linolenic acid, or [1-14C]-2-HA. Extraction and
fractionation of the total cellular lipid extract demon-
strated that the label was present in the glycolipid and
phospholipid fractions (data not shown). Saponification
and HPLC analysis of the fractions containing the free
fatty acids, phospholipids, and neutral lipids showed
that the radioactivity was present only as the original un-
saturated fatty acid used, while, in the case of 2-HA, the
label was associated with endogenous fatty acids (Fig-
ure 5A). Thus, intracellular metabolism of 2-HA is radi-
cally different from that of saturated and unsaturated
(mono- and poly-) fatty acids in mycobacteria.
Second, the role of FASI in the metabolism of 2-HA
was studied by using inhibitors of fatty acid biosynthe-
sis. Thiolactomycin (TLM), a well-characterized inhibitor
of the FASII b-ketoacyl-ACP synthetases [19], did not
modify the metabolites that originated from [1-14C]-2-
HA, while cerulenin, an inhibitor of mycobacterial FASI
and FASII b-ketoacyl-ACP synthetases [20], abrogated
the elongation of 2-HA-derived metabolites (Fig-
ure 5B). In this case, palmitic acid, 3-hexadecenoic
acid, and 3-hydroxyhexadecanoic acid were the labeled
metabolites detected. In a comparable manner, 5-
chloro-pyrazynamide (5-Cl-PZA), a specific inhibitor of
the M. smegmatis FASI enzyme [21, 22], inhibited elon-
gation of 2-HA metabolites. Thus, a functional FASI is
required for the conversion of 2-HA into longer-chain
fatty acids.Long-Chain 3-Alkynoic Acids Are Potent Inhibitors
of b-Oxidation in Mycobacteria
In the previous sections, an analysis of the metabolism
and mechanism of action of a set of isomeric long-chain
alkynoic acids was described. The biological activities
of alkynoic acids are far more diverse than the herein de-
scribed inhibition of fatty acid biosynthesis, including in-
hibition of eukaryotic u-fatty acid hydroxylases [23] and
enzymes of the b-oxidation pathway such as acyl-CoA
dehydrogenases [24] and 3-ketoacyl thiolases [25].
Therefore, it was important to test the effect of long-
chain 2- and 3-alkynoic acids on the b-oxidation path-
way, since this pathway is a plausible candidate for
the generation of 3-KHA. The observation that the con-
centration of [1-14C]-3-HA produced from [1-14C]-2-HA
increased upon treatment of cell cultures with high con-
centrations of 2-HA led us to hypothesize that 3-HA
might inhibit fatty acid degradation, thus allowing for
the accumulation of 3-KHA seen in our samples. This hy-
pothesis was tested by treating M. smegmatis (grown
with palmitic or oleic acid as a carbon source) with
2- or 3-HA (50 mg/ml) for 1 hr before the addition of
[U-14C]-palmitic acid. Inhibition of the b-oxidation path-
way would impair the ability of the cells to produce
14CO2 from the radiolabeled fatty acid. A 60% reduction
of the production of 14CO2 was observed in samples
treated with 2-HA compared to untreated samples.
The inhibition of 3-HA was more severe, reaching 90%
inhibition. This confirms that 3-HA is a potent inhibitor
of b-oxidation in M. smegmatis, which could lead to
the accumulation of 3-KHA observed in our system.
High Levels of 3-KHA Inhibit Fatty Acid
Biosynthesis in M. smegmatis
At concentrations of 2-HA above 10 mg/ml, M. smeg-
matis accumulates 3-hydroxyhexadecanoic acid and
3-KHA. In an attempt to identify the molecule(s) respon-
sible for the inhibition of fatty acid biosynthesis, we an-
alyzed the effect of both intermediates on growth and
synthesis of fatty acids. Fatty acids from M. smegmatis
Activity of 2-Alkynoic Acids on Mycobacteria
303cultures treated with 3-hydroxyhexadecanoic acid
(50 mg/ml) were extracted from the supernatant and
cell pellet and analyzed by HPLC. 3-Hydroxyhexadeca-
noic acid was present in both fractions (data not shown),
indicating that this compound was transported inside
the cell but was not metabolized. The addition of 3-hy-
droxyhexadecanoic acid (50 mg/ml) to early log-phase
cultures of M. smegmatis did not cause growth inhibi-
tion. At the same time, MIC determination showed that
3-hydroxyhexadecanoic acid had no effect on cell num-
ber or colony size at the highest concentration tested
(120 mg/ml).
In contrast, 3-KHA was detected neither in the culture
supernatant nor in the cell pellet. This result suggests
that this molecule could have been transported and
degraded or used for biosynthesis. Determination of
its activity on solid media showed no change in cell via-
bility or colony size at the highest concentration used
(120 mg/ml). Surprisingly, treatment of early log-phase
cultures with increasing concentrations of 3-KHA (10–
50 mg/ml) showed a decrease in the growth rate. In order
to test if an inhibition of fatty acid biosynthesis took
place at the same time as the growth arrest, mid-log
phase cultures of M. smegmatis were treated with
3-KHA at 10, 25, or 50 mg/ml for 30 min, followed by
the addition of [1-14C]-acetate for 30 min. Analysis of
the labeled mycolic acids and fatty acids showed that
their synthesis was inhibited when high concentrations
of 3-KHA were used (Figure 3D). An equal concentration
of 3-hydroxyhexadecanoic acid failed to inhibit fatty
acid synthesis, in total agreement with its lack of effect
on the growth of mycobacteria in both liquid and solid
media. The block on the synthesis was relieved after
3 hr of incubation, as found by full restoration of the in-
corporation of the label (Figure 3D). Therefore, accumu-
lation of 3-KHA transiently blocks fatty acid biosynthesis
in mycobacteria.
Antimycobacterial Activity of 3-KHA Requires
Inhibition of the b-Oxidation Pathway
3-KHA temporarily inhibits both FASI and FASII systems
in mycobacteria. 2-HA is partially converted into 3-HA,
which inhibits fatty acid biosynthesis and the b-oxida-
tion cycle, suggesting that the toxicity of 2-HA may
be a consequence of the inhibition mediated by 3-HA,
with the subsequent accumulation of 3-KHA. To test
this hypothesis, we analyzed the effect of the addition
of 3-HA on cultures of M. smegmatis treated with in-
creasing concentrations of 3-KHA. Low concentrations
of 3-HA (10–25 mg/ml) had a negligible effect on growth;
however, in combination with increasing concentrations
of 3-KHA, an inhibitory effect on the growth of M. smeg-
matis was observed (data not shown). Accordingly, in-
corporation of [1-14C]-acetate is severely decreased in
cultures treated with 3-KHA (50 mg/ml), 3-HA (10 and
25 mg/ml), or a combination of both compounds for
30 min (Figure 3D). While the toxic effect is reversed
within a doubling time for all of the compounds added
independently, the treatment of the cultures with a 2:1
mixture of 3-KHA and 3-HA blocked fatty acid biosyn-
thesis even at the longest time point analyzed (9 hr),
which correlates with the biological action of 2-HA. In
summary, our results indicate that 2-HA acts through
the combined mechanism of action of the two major me-tabolites, 3-HA and 3-KHA, which sets the stage for a
novel concept for the design of antimycobacterial
agents.
Discussion
In this report, the mechanism of action of alkynoic acids
on mycobacteria is described. Long-chain 2-alkynoic
acids are cidal antimycobacterial agents that inhibit
the growth of M. smegmatis and M. bovis BCG. Like
the first-line antituberculosis agents isoniazid and pyra-
zinamide, these compounds are not active as such, but
they require metabolization. Wood and Lee showed that
2-HA inhibited the elongation of fatty acids longer than
palmitic acid in liver microsomes [26]. Based on the me-
tabolites detected, they postulated that, upon transport
and esterification into acyl-CoA, 2-HA could be the sub-
strate for a hydratase forming 3-KHA, or it could be iso-
merized by an acetylenic acid isomerase to a 2,3-allenyl-
fatty acid, followed by conversion to 3-HA. We propose
that a comparable pathway, schematically described in
Figure 6, takes place in M. smegmatis since similar me-
tabolites were detected. Although a D2,3-allenyl-con-
taining fatty acid was not found in any of our fatty acid
extracts, the identification of 3-hexadecenoic acid 10
and 3-HA 9 suggests that the 2,3-allenyl moiety 8 is
formed in the mycobacterial cell. Isomerization of 8
would yield 3-HA, while reduction of the D2 double
bond would form 10. In fact, we detected these com-
pounds in M. smegmatis fatty acid preparations. The
fact that a 3-acetylenic acid isomerase activity has
been found in M. smegmatis supports our hypothesis
[27]. Furthermore, beef liver crotonase was reported to
hydrate 2,3-allenic thioesters [28]. Moreover, a recent
publication [29] showed that the liver mitochondrial
enoyl-CoA hydratase (crotonase) was able to catalyze
the hydration of 3-octynoyl-CoA, yielding 3-ketoocta-
noyl-CoA.
Treatment of M. smegmatis cultures with high con-
centrations of 2-HA leads to inhibition of fatty acid bio-
synthesis and fatty acid degradation, via accumulation
of 3-HA and 3-KHA. The bacterial b-oxidation cycle de-
grades fatty acids by cleavage of two-carbon units
that are released as acetyl-CoA. Components of this cy-
cle include FadD (acyl-CoA synthetase), FadE (acyl-CoA
dehydrogenase), and a tetrameric complex formed by
two molecules of FadB (having activities of enoyl-CoA
hydratase, enoyl-isomerase, and 3-hydroxyacyl-CoA
dehydrogenase) and two molecules of FadA (having
the activity of 3-ketoacyl-thiolase). One turn of the cycle
thus results in the shortening of a fatty acyl chain by two
carbons. M. smegmatis is unable to utilize 2-HA as the
sole source of carbon and energy (H.R.M., unpublished
data), raising the question of why 2-HA is not totally de-
graded to acetyl-CoA. Holland et al. showed that 3-buty-
noyl-CoA irreversibly inhibits the activity of a mammalian
3-ketoacyl thiolase in vitro [30]. Our results are compat-
ible with an inhibition of the degradation of 2-HA at the
level of the thiolytic cleavage step. As we showed that
3-HA inhibits the degradation pathway, we suggest (al-
though direct evidence is necessary) that 3-HA targets
a long-chain 3-ketoacyl thiolase, a possibility compati-
ble with the observed accumulation of 3-KHA.
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The proposed pathway is based on the metabolites derived from [1-14C]-2-HA and detected by HPLC. The identification key for the compounds
shown is as follows: (1) 2-HA, (2) 2-hexadecynoyl-CoA, (3) 3-ketohexadecanoyl-CoA, (4) 3-hydroxyhexadecanoyl-CoA, (5) 2-trans-hexadecenoyl-
CoA, (6) hexadecanoyl-CoA, (7) hexadecanoyl-ACP, (8) 2,3-hexadecadienoyl-CoA, (9) 3-hexadecynoyl-CoA, (10) 3-hexadecenoyl-CoA.The major 2-HA-derived metabolite, 3-KHA, exerts
a transitory toxic effect on the FASI- and FASII-mediated
synthesis of fatty acids. In the absence of fatty acid elon-
gation, cleavage of 3-KHA by a long-chain 3-ketoacyl
thiolase would be the most likely explanation for the re-
covery of fatty acid biosynthesis observed in M. smeg-
matis treated with low concentrations of 2-HA. Although
no long-chain 3-ketoacyl thiolase has been identified yet
in mycobacteria, the M. tuberculosis genome encodes
for three putative ketoacyl-CoA thiolases (fadA3,
Rv0914c,Rv3523) [31]. Therefore, a conceivable mecha-
nism for the 2-HA-mediated antimycobacterial effect is
the accumulation of 3-KHA when the long-chain thiolase
is inhibited, possibly by 3-HA. Our reconstitution exper-
iments support this mechanism since neither 3-KHA nor
3-HA alone were able to significantly affect the myco-
bacterial growth or incorporation of [1-14C]-acetate.
Both compounds added simultaneously at a 2:1 ratio
yielded the same inhibitory effect displayed by 2-HA,
demonstrating that growth inhibition is a consequence
of the dual action of both 3-HA and 3-KHA. Therefore,
we propose that the mechanism of action of 2-HA is
based on the formation of the two major metabolites,
3-KHA and 3-HA, resulting in the dual inhibition of fatty
acid biosynthesis and fatty acid degradation in myco-
bacteria, two pathways of extreme importance. Indeed,
from a pharmacological point of view, fatty acid biosyn-
thesis is the target of several antitubercular drugs, in-
cluding pyrazinamide [22], isoniazid, or ethionamide [8,
10]. Physiologically, fatty acids are the preferred carbon
source for mycobacteria isolated from animal lungs [32].
Deletion of M. tuberculosis isocitrate lyase 1 and 2
genes (key enzymes of the glyoxylate cycle) caused se-
vere growth inhibition of M. tuberculosis in mice [33],thus emphasizing the predominant role that fatty acid
degradation plays in the intracellular survival capacity
of this pathogen.
It is interesting to note that the effect of 2-HA on eu-
karyotic systems is different from that observed in my-
cobacteria [26]. Addition of 2-HA to rat liver microsomal
preparations inhibited the synthesis of stearic acid
(C18:0) and longer-chain fatty acids and had no effect
on the synthesis of palmitic acid; the same effect was
seen in rats fed with 2-HA [26, 34]. In M. smegmatis,
2-HA blocked the de novo synthesis of fatty acids as
well as the synthesis of mycolic acids, which could be
considered to be an ‘‘elongation’’ step. Based on our
postulated metabolic pathway for 2-HA (Figure 6), we
propose that the colocalization of both fatty acid synthe-
sis and degradation is the key to explain these observa-
tions. If some of the enzymes of the b-oxidation cycle are
required for the transformation of 2-HA, then they must
be in the same compartment as the target system, the
fatty acid biosynthesis system. The fatty acid degrada-
tion and FASI pathways are located in the mycobacterial
cytoplasm, while FASII has been proposed to be loosely
associated to the plasma membrane. Importantly none
of these enzymatic complexes seems to be located in
a subcellular compartment; therefore, the inhibitory me-
tabolite has direct access to both FASI and FASII. This
situation contrasts with the microsomal system, in
which only the fatty acid elongation system colocalizes
with the enzymes of the b-oxidation pathway. Since
FASI is cytoplasmic, it is not inhibited. Thus, 2-alkynoic
acids could be used specifically against bacteria with-
out toxicity for the host. In this scenario, the mechanism
of action of 2-alkynoic acids represents a reasonable
approach for the rational design of new bifunctional
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acids will confirm the hypothetical role of the mentioned
enzymes and also identify other targets affected by
2- and 3-HA/OA, increasing our knowledge of the myco-
bacterial lipid metabolism.
Significance
Long-chain alkynoic acids have antimycobacterial
properties in the 10–40 mM range. Their inhibitory ef-
fect onM. smegmatis requires a combination of a spe-
cific chain length (16 or 18 carbons) and the triple bond
at position 2. We found that, at low concentrations,
2-hexadecynoic acid and 2-octadecynoic acid are me-
tabolized to palmitic acid and elongated into endoge-
nous fatty acids and mycolic acids in M. smegmatis
andM. bovisBCG. At toxic concentrations, these com-
pounds inhibit fatty acid degradation and fatty acid
synthesis, resulting in cell death. This is the first exam-
ple of an antibacterial compound inhibiting several
pathways to achieve its effect. Furthermore, these
compounds are another example of antimycobacterial
agents, which require activation in order to be effec-
tive. We propose that the different effects seen in the
eukaryotic versus mycobacterial systems stem from
the different intracellular location of the enzyme com-
ponents of the fatty acid degradation and fatty acid
biosynthesis cycles. M. tuberculosis possesses a
unique metabolism of lipids, ranging from the several
pathways involved in the synthesis of complex lipids
to the numerous enzymes taking part in fatty acid deg-
radation. By inhibiting de novo fatty acid biosynthesis,
fatty acid elongation, and fatty acid degradation,
2-alkynoic acids offer new tools by which to analyze
these systems in mycobacteria.
Experimental Procedures
Experimental Reagents
Sources for the supplies were: Amersham Corp., [1-14C]-palmitic
acid (specific activity 55 Ci/mol); NEN, [U-14C]-palmitic acid
(850 Ci/mol) and [1-14C]-acetic acid (specific activity of 56 Ci/mol);
American Radiochemical Company, [1-14C]-linoleic acid, [1-14C]-
linolenic acid, and [1-14C]-oleic acid (specific activity of these three
products was 55 Ci/mol). [1-14C]-2-Hexadecynoic acid (specific ac-
tivity of 56 Ci/mol) was purchased from Moravek Biochemicals
(Brea, CA). Thin-layer chromatography (TLC) plates and reagents
for lipid detection were obtained from Alltech (Deerfield, IL), Fisher
(Pittsburgh, PA), or Sigma (St. Louis, MO). Cerulenin was purchased
from Sigma, and 5-chloro-pyrazinamide and thiolactomycin were
the generous gifts from John Welsh (State University of New York,
Albany, Albany, NY) and David Fidock (Albert Einstein College of
Medicine, Bronx, NY), respectively. Fatty acid and lipid standards
were obtained from Sigma or Indofine (Somerville, NJ). Microbiolog-
ical media was purchased from Difco. All other biochemicals and
solvents were reagent grade or better. The following compounds
were prepared as described previously: 2-alkenoic acids [10], 3-hex-
adecenoic acid [35], and 3-KHA [36].
Bacterial Strains and Growth Conditions
M. smegmatis strains and Corynebacterium glutamicum ATCC
13032 were grown at 37ºC and 120 rpm in Mueller-Hinton or Sauton
broth containing Tween 80 (0.02%, v/v) and were plated on Mueller-
Hinton agar. mc22399 was grown on Mueller-Hinton broth supple-
mented with 20 mg/ml kanamycin. M. bovis var. BCG and M. tuber-
culosis H37Rv were grown at 37ºC in Roller bottles (Corning) at
40 rpm in Sauton supplemented with Tween 80 (0.02%, v/v) and
were plated on Middlebrook 7H10 medium with the addition of10% OADC enrichment. Basal liquid medium for M. smegmatis
was prepared according to Hartmans and de Bont [37], with the ad-
dition of methyl oleate or methyl palmitate (1.0 g/l) as carbon source.
Synthesis of Alkynoic Acids
2-Alkynoic acids were synthesized as follows: (a) 1-hydroxyalkanes
were converted into the corresponding 1-bromoalkanes by using
phosphorus tribromide in diethyl ether; (b) the alkyl bromides were
reacted with lithium acetylide ethylenediamine complex in dimethyl
sulfoxide (DMSO) at room temperature; (c) the resulting 1-alkynes
were converted to the lithium salts with n-butyllithium (n-BuLi) in tet-
rahydrofuran (THF) at 223ºC [38]; and (d) the latter were quenched
by bubbling CO2 generated from dry ice into the solution containing
the alkynyllithium. Acidification with HCl (6 N) and extraction with di-
ethyl ether gave 2-alkynoic acids, which were purified by silica gel
chromatography and recrystallization from hexane. 3-Alkynoic acids
were obtained from 3-butyn-1-ol in four steps: (a) protection of the
alcohol group as a tetrahydropyranyl (THP) ether; (b) treatment of
the alkyne with n-BuLi in THF at 278ºC, followed by coupling of
the resulting lithium salt with 1-bromoalkane in the presence of hex-
amethylphosphoramide to form the 3-alkyn-1-OTHP [39]; (c) hydro-
lysis of the THP ether with acidic methanol; and (d) oxidation of the
resulting alcohol with chromium trioxide. 4- and 5-Alkynoic acids
were prepared in a similar way by using 4-pentyl-1-ol or 5-hexyn-
1-ol as the starting material. The compounds were purified by silica
gel chromatography, followed by recrystallization from hexane. The
structures of all of the products were confirmed by 1H- and 13C-NMR
spectroscopy.
Determination of the Minimum Inhibitory Concentration
Liquid MIC values were determined by using a modified microbroth
dilution assay [40]. The MIC was defined as the lowest concentration
of alkynoic acid that prevented visible growth, and it was the aver-
age value of five cultures. Solid MIC values were obtained by using
cultures of five independent colonies of C. glutamicum ATCC 13032
and M. smegmatis, grown to an OD600 of 0.8–1.0 and diluted to give
104 CFU/ml. Aliquots (100 ml) of each culture of C. glutamicum and
M. smegmatis were plated on Mueller-Hinton plates containing in-
creasing amounts of the compounds to be tested. In both solid
and liquid MICs, the results were read after 4 days at 37ºC. For
M. bovis BCG and M. tuberculosis, the MIC was determined by
growing the strains in Sauton media containing increasing concen-
trations of 2-HA and 2-OA and plating serial dilutions after 7 and
30 days of treatment. The MIC was defined as the concentration of
drug causing a 99.9% reduction in the CFU/ml of the indicator strain.
Immunoblotting
Aliquots (10 ml) of culture were harvested at mid-log phase. Cells
were then resuspended in 0.8 ml phosphate-buffered saline
(20 mM K2HPO4 [pH 7.5], 0.15 M NaCl) and disrupted during
10 min by using a Branson Sonifier 450. Protein concentrations
were determined by using the BCA Protein Assay Reagent kit (Pierce
Europe, Oud-Beijerland, Netherlands). Equal amounts of proteins
(25 mg) were then separated on a SDS-polyacrylamide gel. Proteins
were transferred onto a Hybond-C Extra membrane (Amersham).
Membranes were then saturated with 5% dry milk in PBS-0.1%
Tween 20 and incubated overnight with rat anti-KasA antibodies
raised against the M. tuberculosis KasA protein (1/500 dilution),
washed, and incubated with anti-rat antibodies conjugated to alka-
line phosphatase (1/7000 dilution; Promega).
Labeling of Bacterial Cultures
Early-log cultures of M. smegmatis or M. bovis BCG (OD600 ofw0.4)
were treated at 37ºC with different concentrations of 2-HA for 30 min
and 12 hr, respectively, and then labeled (0.5 mCi/ml) for 30 min and
1 hr, respectively, at 37ºC. Cell pellets were washed twice with 1%
bovine serum albumin in water to eliminate the carry-over of ad-
sorbed fatty acids when polar lipids were analyzed. Cell pellets
were used immediately or stored at 220ºC before use.
Mycolic Acid and Phospholipid Analysis
Mycolic acid methyl esters (MAMEs) and fatty acid methyl esters
(FAMEs) were prepared by alkaline treatment of the bacterial pellets
as described previously [10]. Phospholipid extraction was done
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pended in 100 ml chloroform/methanol (1/1, v/v) prior to analysis
by TLC.
TLC Systems
Radioactive aliquots (w20,000 cpm) of the different samples ana-
lyzed were separated on silica gel G plates. MAMEs and FAMEs
were separated by two developments by using hexane/ethyl acetate
(9/1, v/v) as a solvent system. Mycobacterial phospholipids were
fractionated on silica gel G plates developed once in chloroform/
methanol/water (60/24/1, v/v/v). Fractions containing nonpolar
lipids and free fatty acids, obtained as an acetone-soluble fraction,
were analyzed on silica gel G plates with hexane/ethyl acetate/ace-
tic acid (80/20/0.5, v/v/v) as a solvent system. Bands were visualized
by spraying with orcinol, phosphomolybdic acid, and ninhydrin (de-
tecting glycolipids, phospholipids, and glycopeptidolipids, respec-
tively). Incorporation of radiolabeled precursors was detected by
autoradiography after exposure at 280ºC for 2 days.
Fatty Acid Analysis by High-Performance
Liquid Chromatography
Fatty acid p-bromophenacyl esters were prepared by alkaline treat-
ment and derivatization as described previously [10]. The esters
were analyzed on a Hewlett-Packard model HP1100 HPLC equipped
with a thermostated column compartment set at 45ºC, a diode array
detector set at 260 nm, and an IN/US b-RAM flowthrough radioiso-
tope b-g radiation detector, by using a reverse-phase C18 column
(4.6 3 150 mm, 3 mm column diameter, Alltima C18 from Alltech).
The flow rate was 2 ml/min. The mobile phase was acetonitrile-water
used as an isocratic elution (83/17, v/v) for the first 20 min, followed
by a linear increase to 100% acetonitrile for 2 min and held at 100%
acetonitrile for 18 min. In-Flow TM ES (IN/US Systems, Inc., Tampa,
FL) was used to detect the 14C-labeled fatty acid esters (3:1 ratio
with column eluant). The peaks were identified by comparison with
chromatograms of fatty acid standards derivatized to theirp-bromo-
phenacyl esters.
Determination of Inhibition of b-Oxidation by Alkynoic Acids
The ability of 2- and 3-HA to inhibit degradation of fatty acids was
tested by measuring the production of 14CO2 from [U-
14C]-palmitic
acid. Briefly, M. smegmatis cultures were grown in basal medium
with either methyl palmitate or methyl oleate (0.1%, v/v) as the car-
bon source. Early stationary phase cultures were centrifuged at
room temperature, washed twice with warm basal medium devoid
of a carbon source, concentrated 10-fold in the same medium,
and treated with alkynoic acids at appropriate concentrations for
1 hr at 37ºC. After this time, [1-14C]-palmitic acid (2 mCi/ml) was
added, and the incubation was allowed to proceed overnight. The
14CO2 generated was trapped as BaCO3 in a filter paper disk impreg-
nated with Ba(OH)2 that was previously placed in the recessed lid of
the vial. The filter disk was removed, and the trapped radioactivity
was determined by liquid scintillation counting.
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